Skip to main content

ORIGINAL RESEARCH article

Front. Immunol., 11 September 2020
Sec. Inflammation

RETRACTED: Inhibition of Bcl2L12 Attenuates Eosinophilia-Related Inflammation in the Heart

Retracted
\r\nXiao Chen&#x;Xiao Chen1Mei-Zhen Zhao&#x;Mei-Zhen Zhao2Bei-Ping Miao&#x;Bei-Ping Miao3Zhi-Qiang LiuZhi-Qiang Liu2Gui YangGui Yang4Jiang-Qi LiuJiang-Qi Liu2Ping-Chang Yang,
Ping-Chang Yang2,5*Jiang-Ping Song
Jiang-Ping Song1*
  • 1State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  • 2Research Center of Allergy & Immunology, Shenzhen University School of Medicine, Shenzhen, China
  • 3Department of Otolaryngology, First Affiliated Hospital of Shenzhen University, Shenzhen, China
  • 4Department of Otolaryngology, Longgang Central Hospital, Shenzhen, China
  • 5Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Shenzhen, China

Citation: Chen X, Zhao M-Z, Miao B-P, Liu Z-Q, Yang G, Liu J-Q, Yang P-C and Song J-P (2020) Inhibition of Bcl2L12 Attenuates Eosinophilia-Related Inflammation in the Heart. Front. Immunol. 11:1955. doi: 10.3389/fimmu.2020.01955

Received: 05 March 2020; Accepted: 20 July 2020;
Published: 11 September 2020; Retracted: 05 June 2023.

Edited by:

Guochang Hu, University of Illinois at Chicago, United States

Reviewed by:

VijayaKumar Sukumaran, Qatar University, Qatar
Gabriela Kania, University Hospital Zürich, Switzerland
Chandirasegaran Massilamany, CRISPR Therapeutics, Inc., United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.